{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:43:21Z","timestamp":1776732201846,"version":"3.51.2"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02635-2","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:04:19Z","timestamp":1776729859000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sirolimus plus roxadustat synergistically enhances immunosuppression and erythropoiesis in pure red cell aplasia: a multicenter trial"],"prefix":"10.1038","volume":"11","author":[{"given":"Hong","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjing","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiyun","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zefa","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiurong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanqun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingzhi","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohui","family":"Shangguan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinge","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiqing","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongxia","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liansheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Limin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6312-3863","authenticated-orcid":false,"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"2635_CR1","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/j.1365-2141.2008.07216.x","volume":"142","author":"K Sawada","year":"2008","unstructured":"Sawada, K., Fujishima, N. & Hirokawa, M. Acquired pure red cell aplasia: updated review of treatment. Br. J. Haematol. 142, 505\u2013514 (2008).","journal-title":"Br. J. Haematol."},{"key":"2635_CR2","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1182\/blood-2016-05-717140","volume":"128","author":"RT Means Jr","year":"2016","unstructured":"Means, R. T. Jr Pure red cell aplasia. Blood 128, 2504\u20132509 (2016).","journal-title":"Blood"},{"key":"2635_CR3","doi-asserted-by":"publisher","first-page":"6451","DOI":"10.1182\/bloodadvances.2023010587","volume":"7","author":"H Lobbes","year":"2023","unstructured":"Lobbes, H., Lega, J. C., Le Guenno, G., Ruivard, M. & Mainbourg, S. Treatment strategy for acquired pure red cell aplasia: a systematic review and meta-analysis. Blood Adv. 7, 6451\u20136465 (2023).","journal-title":"Blood Adv."},{"key":"2635_CR4","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3324\/haematol.2017.175810","volume":"103","author":"SK Balasubramanian","year":"2018","unstructured":"Balasubramanian, S. K. et al. Rational management approach to pure red cell aplasia. Haematologica 103, 221\u2013230 (2018).","journal-title":"Haematologica"},{"key":"2635_CR5","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3324\/haematol.11192","volume":"92","author":"K Sawada","year":"2007","unstructured":"Sawada, K. et al. Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. A nationwide cohort study in Japan for the PRCA Collaborative Study Group. Haematologica 92, 1021\u20131028 (2007).","journal-title":"Haematologica"},{"key":"2635_CR6","doi-asserted-by":"publisher","first-page":"E294","DOI":"10.1002\/ajh.25609","volume":"94","author":"C Halkes","year":"2019","unstructured":"Halkes, C. et al. Allogeneic stem cell transplantation for acquired pure red cell aplasia. Am. J. Hematol. 94, E294\u2013E296 (2019).","journal-title":"Am. J. Hematol."},{"key":"2635_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/ajh.10421","volume":"74","author":"SB Tseng","year":"2003","unstructured":"Tseng, S. B. et al. Successful treatment of acquired pure red cell aplasia (PRCA) by allogeneic peripheral blood stem cell transplantation. Am. J. Hematol. 74, 273\u2013275 (2003).","journal-title":"Am. J. Hematol."},{"key":"2635_CR8","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/ki.2014.144","volume":"86","author":"T Comont","year":"2014","unstructured":"Comont, T., Bournet, B., Casadevall, N., Chauveau, D. & Faguer, S. Rituximab in pure red-cell aplasia secondary to anti-erythropoietin antibodies. Kidney Int 86, 210\u2013211 (2014).","journal-title":"Kidney Int"},{"key":"2635_CR9","doi-asserted-by":"publisher","first-page":"3995","DOI":"10.1182\/blood.V97.12.3995","volume":"97","author":"M Zecca","year":"2001","unstructured":"Zecca, M., De Stefano, P., Nobili, B. & Locatelli, F. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood 97, 3995\u20133997 (2001).","journal-title":"Blood"},{"key":"2635_CR10","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/j.1365-2141.2009.08027.x","volume":"148","author":"AM Risitano","year":"2010","unstructured":"Risitano, A. M. et al. Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. Br. J. Haematol. 148, 791\u2013796 (2010).","journal-title":"Br. J. Haematol."},{"key":"2635_CR11","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1038\/sj.leu.2403956","volume":"19","author":"C Schutzinger","year":"2005","unstructured":"Schutzinger, C. et al. Remission of pure red cell aplasia in T-cell receptor gammadelta-large granular lymphocyte leukemia after therapy with low-dose alemtuzumab. Leukemia 19, 2005\u20132008 (2005).","journal-title":"Leukemia"},{"key":"2635_CR12","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.leukres.2005.02.018","volume":"29","author":"WY Au","year":"2005","unstructured":"Au, W. Y., Lam, C. C., Chim, C. S., Pang, A. W. & Kwong, Y. L. Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia. Leuk. Res. 29, 1213\u20131215 (2005).","journal-title":"Leuk. Res."},{"key":"2635_CR13","doi-asserted-by":"publisher","first-page":"7S","DOI":"10.1016\/S0041-1345(03)00211-2","volume":"35","author":"SN Sehgal","year":"2003","unstructured":"Sehgal, S. N. Sirolimus: its discovery, biological properties, and mechanism of action. Transpl. Proc. 35, 7S\u201314S (2003).","journal-title":"Transpl. Proc."},{"key":"2635_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cmet.2014.01.001","volume":"19","author":"J Li","year":"2014","unstructured":"Li, J., Kim, S. G. & Blenis, J. Rapamycin: one drug, many effects. Cell Metab. 19, 373\u2013379 (2014).","journal-title":"Cell Metab."},{"key":"2635_CR15","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.semarthrit.2020.07.006","volume":"50","author":"L Ji","year":"2020","unstructured":"Ji, L., Xie, W. & Zhang, Z. Efficacy and safety of sirolimus in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Semin. Arthritis Rheum. 50, 1073\u20131080 (2020).","journal-title":"Semin. Arthritis Rheum."},{"key":"2635_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2015-07-657981","volume":"127","author":"KL Bride","year":"2016","unstructured":"Bride, K. L. et al. Sirolimus is effective in relapsed\/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood 127, 17\u201328 (2016).","journal-title":"Blood"},{"key":"2635_CR17","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1007\/s00277-018-3431-5","volume":"97","author":"Z Long","year":"2018","unstructured":"Long, Z. et al. Successful treatment of refractory\/relapsed acquired pure red cell aplasia with sirolimus. Ann. Hematol. 97, 2047\u20132054 (2018).","journal-title":"Ann. Hematol."},{"key":"2635_CR18","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00277-020-03946-2","volume":"99","author":"Z Chen","year":"2020","unstructured":"Chen, Z., Liu, X., Chen, M., Yang, C. & Han, B. Successful sirolimus treatment of patients with pure red cell aplasia complicated with renal insufficiency. Ann. Hematol. 99, 737\u2013741 (2020).","journal-title":"Ann. Hematol."},{"key":"2635_CR19","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/s41375-022-01532-1","volume":"36","author":"Y Huang","year":"2022","unstructured":"Huang, Y. et al. Sirolimus is effective for refractory\/relapsed\/intolerant acquired pure red cell aplasia: results of a prospective single-institutional trial. Leukemia 36, 1351\u20131360 (2022).","journal-title":"Leukemia"},{"key":"2635_CR20","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","volume":"381","author":"N Chen","year":"2019","unstructured":"Chen, N. et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N. Engl. J. Med. 381, 1011\u20131022 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2635_CR21","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","volume":"381","author":"N Chen","year":"2019","unstructured":"Chen, N. et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. N. Engl. J. Med. 381, 1001\u20131010 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2635_CR22","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/ajh.26397","volume":"97","author":"DH Henry","year":"2022","unstructured":"Henry, D. H. et al. Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: open-label, dose-selection, lead-in stage of a phase 3 study. Am. J. Hematol.97, 174\u2013184 (2022).","journal-title":"Am. J. Hematol."},{"key":"2635_CR23","first-page":"1541","volume":"60","author":"H Zhong","year":"2000","unstructured":"Zhong, H. et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor\/phosphatidylinositol 3-kinase\/PTEN\/AKT\/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 60, 1541\u20131545 (2000).","journal-title":"Cancer Res."},{"key":"2635_CR24","doi-asserted-by":"publisher","first-page":"27975","DOI":"10.1074\/jbc.M204152200","volume":"277","author":"C Treins","year":"2002","unstructured":"Treins, C., Giorgetti-Peraldi, S., Murdaca, J., Semenza, G. L. & Van Obberghen, E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase\/target of rapamycin-dependent signaling pathway. J. Biol. Chem. 277, 27975\u201327981 (2002).","journal-title":"J. Biol. Chem."},{"key":"2635_CR25","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1073\/pnas.1014769108","volume":"108","author":"Q Sun","year":"2011","unstructured":"Sun, Q. et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc. Natl. Acad. Sci. USA 108, 4129\u20134134 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2635_CR26","doi-asserted-by":"publisher","first-page":"7004","DOI":"10.1128\/MCB.22.20.7004-7014.2002","volume":"22","author":"CC Hudson","year":"2002","unstructured":"Hudson, C. C. et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol. Cell Biol. 22, 7004\u20137014 (2002).","journal-title":"Mol. Cell Biol."},{"key":"2635_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1365-2141.2009.07595.x","volume":"145","author":"DT Teachey","year":"2009","unstructured":"Teachey, D. T. et al. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br. J. Haematol. 145, 101\u2013106 (2009).","journal-title":"Br. J. Haematol."},{"key":"2635_CR28","doi-asserted-by":"publisher","first-page":"548085","DOI":"10.1155\/2013\/548085","volume":"2013","author":"J Li","year":"2013","unstructured":"Li, J. et al. Effects of rapamycin combined with low dose prednisone in patients with chronic immune thrombocytopenia. Clin. Dev. Immunol. 2013, 548085 (2013).","journal-title":"Clin. Dev. Immunol."},{"key":"2635_CR29","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/bjh.13376","volume":"169","author":"M Hirokawa","year":"2015","unstructured":"Hirokawa, M. et al. Long-term outcome of patients with acquired chronic pure red cell aplasia (PRCA) following immunosuppressive therapy: a final report of the nationwide cohort study in 2004\/2006 by the Japan PRCA collaborative study group. Br. J. Haematol. 169, 879\u2013886 (2015).","journal-title":"Br. J. Haematol."},{"key":"2635_CR30","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s00277-022-04847-2","volume":"101","author":"X Wu","year":"2022","unstructured":"Wu, X. et al. Clinical characteristics and outcomes of 100 adult patients with pure red cell aplasia. Ann. Hematol. 101, 1493\u20131498 (2022).","journal-title":"Ann. Hematol."},{"key":"2635_CR31","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1182\/blood.2021010898","volume":"137","author":"C Gurnari","year":"2021","unstructured":"Gurnari, C. & Maciejewski, J. P. How I manage acquired pure red cell aplasia in adults. Blood 137, 2001\u20132009 (2021).","journal-title":"Blood"},{"key":"2635_CR32","doi-asserted-by":"publisher","first-page":"5291","DOI":"10.4049\/jimmunol.1301181","volume":"191","author":"P Zhang","year":"2013","unstructured":"Zhang, P. et al. Induced regulatory T cells promote tolerance when stabilized by rapamycin and IL-2 in vivo. J. Immunol. 191, 5291\u20135303 (2013).","journal-title":"J. Immunol."},{"key":"2635_CR33","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/cncr.10245","volume":"94","author":"D Cella","year":"2002","unstructured":"Cella, D., Lai, J. S., Chang, C. H., Peterman, A. & Slavin, M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 94, 528\u2013538 (2002).","journal-title":"Cancer"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02635-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02635-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02635-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:04:21Z","timestamp":1776729861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02635-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2635"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02635-2","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"2 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"143"}}